#43 Rethinking medical device safety, part 1 – Omar Aimer Podcast Por  arte de portada

#43 Rethinking medical device safety, part 1 – Omar Aimer

#43 Rethinking medical device safety, part 1 – Omar Aimer

Escúchala gratis

Ver detalles del espectáculo

Medical device pharmacovigilance is complicated. Alongside clinical safety, there are technology risks, from cybersecurity threats to outdated software, that can leave patients vulnerable.

In this two-part episode, Omar Aimer, president of ISoP and former co-lead of the Medical Device Safety Special Interest Group, discusses the challenges with medical device safety monitoring and what needs to change to keep patients safe.

Tune in to find out:

  • What defines a medical device and how prevalent they are in our society
  • Why device safety monitoring is different from medicines and vaccines, and where current surveillance still falls short
  • How global initiatives aim to strengthen safety monitoring standards

Want to know more?

If you would like to learn more on the status and suggestions for future improvements in medical device safety monitoring, Omar has recently published a paper on the topic in the journal Drug Safety, as well as an article for Uppsala Reports.

Much like any other market, AI/ML are fast infiltrating the medical device field, and may require tailored frameworks for effective safety monitoring, as discussed by Babic et al. in their Nature paper.

Founded in 2018, ISoP’s Medical Device Safety Special Interest Group works to develop “best practices and policy in the field of medical device performance monitoring and safety surveillance”.


Join the conversation on social media
Follow us on Facebook, LinkedIn, X, or Bluesky and share your thoughts about the show with the hashtag #DrugSafetyMatters.

Got a story to share?
We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch!

About UMC
Read more about Uppsala Monitoring Centre and how we promote safer use of medicines and vaccines for everyone everywhere.

Todavía no hay opiniones